← 產業報告目錄
Virus-Like Particle Vaccine Market Size, Share & Trends Analysis Report By Application Type (Infectious Diseases, Cancer Immunotherapy, Others), By Stage (Pre-clinical Research Stage, Approved Vaccines), By Distribution Channel (Healthcare Providers, Government Vaccination Programs, Retail Pharmacies), By Region, And By Segment Forecasts, 2023-2031
出版商 InsightAce Analytic產業別 Healthcare & Life Sciences出版日期 2026-02-07頁數 179報告編號 INSIGHTACE-233e74c41b
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
報告摘要
A CAGR of 8.24% is forecasted for the global Virus-Like Particle Vaccine Market over the assessment period of 2023 through 2031.
The Virus-Like Particle Vaccine sector involves a type of vaccine that mimics the structure of viruses but lacks the genetic material necessary for replication and causing disease. This domain has witnessed notable transformation owing to technological breakthroughs and shifting healthcare dynamics.
The market's upward path is underpinned by expanding healthcare spending, technological evolution, and the expanding focus on personalized and precision-based approaches in healthcare.
The market landscape is structured across several key segments—spanning type, application, distribution channel, and region—each contributing uniquely to overall market expansion.
Geographically, North America maintains a leading position owing to advanced infrastructure, high R&D expenditure, and a well-established regulatory environment. Meanwhile, Asia-Pacific is emerging as the fastest-growing region, underpinned by rapid industrialization and expanding end-user bases.
The competitive arena features a mix of established conglomerates and agile innovators, each vying for market position through strategic acquisitions, product launches, and capacity expansion.
Through rigorous analysis of market trends, growth catalysts, restraints, and opportunities, this study offers valuable perspectives for companies, investors, and policymakers navigating this evolving landscape.
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Virus-Like Particle Vaccine Market Snapshot
Chapter 4. Global Virus-Like Particle Vaccine Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter's Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: By Stage Estimates & Trend Analysis
5.1. By Stage, & Market Share, 2020 & 2031
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2031 for the following By Stage:
5.2.1. Pre-clinical Research Stage
5.2.2. Approved Vaccines
Chapter 6. Market Segmentation 2: By Distribution Channel Estimates & Trend Analysis
6.1. By Distribution Channel & Market Share, 2020 & 2031
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2031 for the following By Distribution Channel:
6.2.1. Healthcare Providers
6.2.2. Retail Pharmacies
6.2.3. Government Vaccination Programs
Chapter 7. Market Segmentation 3: By Application Type Estimates & Trend Analysis
7.1. By Application Type & Market Share, 2020 & 2031
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2031 for the following By Application Type:
7.2.1. Infectious Diseases
7.2.2. Cancer Immunotherapy
7.2.3. Others
Chapter 8. Virus-Like Particle Vaccine Market Segmentation 4: Regional Estimates & Trend Analysis
8.1. North America
8.1.1. North America Virus-Like Particle Vaccine Market revenue (US$ Million) estimates and forecasts By Stage, 2019-2031
8.1.2. North America Virus-Like Particle Vaccine Market revenue (US$ Million) estimates and forecasts By Distribution Channel, 2019-2031
8.1.3. North America Virus-Like Particle Vaccine Market revenue (US$ Million) estimates and forecasts By Application Type, 2019-2031
8.1.4. North America Virus-Like Particle Vaccine Market revenue (US$ Million) estimates and forecasts by country, 2019-2031
8.2. Europe
8.2.1. Europe Virus-Like Particle Vaccine Market revenue (US$ Million) By Stage, 2019-2031
8.2.2. Europe Virus-Like Particle Vaccine Market revenue (US$ Million) By Distribution Channel, 2019-2031
8.2.3. Europe Virus-Like Particle Vaccine Market revenue (US$ Million) By Application Type, 2019-2031
8.2.4. Europe Virus-Like Particle Vaccine Market revenue (US$ Million) by country, 2019-2031
8.3. Asia Pacific
8.3.1. Asia Pacific Virus-Like Particle Vaccine Market revenue (US$ Million) By Stage, 2019-2031
8.3.2. Asia Pacific Virus-Like Particle Vaccine Market revenue (US$ Million) By Distribution Channel, 2019-2031
8.3.3. Asia Pacific Virus-Like Particle Vaccine Market revenue (US$ Million) By Application Type, 2019-2031
8.3.4. Asia Pacific Virus-Like Particle Vaccine Market revenue (US$ Million) by country, 2019-2031
8.4. Latin America
8.4.1. Latin America Virus-Like Particle Vaccine Market revenue (US$ Million) By Stage, (US$ Million) 2019-2031
8.4.2. Latin America Virus-Like Particle Vaccine Market revenue (US$ Million) By Distribution Channel, (US$ Million) 2019-2031
8.4.3. Latin America Virus-Like Particle Vaccine Market revenue (US$ Million) By Application Type, (US$ Million) 2019-2031
8.4.4. Latin America Virus-Like Particle Vaccine Market revenue (US$ Million) by country, 2019-2031
8.5. Middle East & Africa
8.5.1. Middle East & Africa Virus-Like Particle Vaccine Market revenue (US$ Million) By Stage, (US$ Million) 2019-2031
8.5.2. Middle East & Africa Virus-Like Particle Vaccine Market revenue (US$ Million) By Distribution Channel, (US$ Million) 2019-2031
8.5.3. Middle East & Africa Virus-Like Particle Vaccine Market revenue (US$ Million) By Application Type, (US$ Million) 2019-2031
8.5.4. Middle East & Africa Virus-Like Particle Vaccine Market revenue (US$ Million) by country, 2019-2031
Chapter 9. Competitive Landscape
9.1. Major Mergers and Acquisitions/Strategic Alliances
9.2. Company Profiles
9.2.1. Novavax
9.2.2. GlaxoSmithKline (GSK)
9.2.3. Merck & Co.
9.2.4. Medicago
9.2.5. Dynavax Technologies
9.2.6. Cytos Biotechnology
9.2.7. IBio
9.2.8. Sanofi Pasteur
9.2.9. Bavarian Nordic
9.2.10. Other Companies.
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們